Aktienanalyse zu Scholar Rock Holding Corp (SRRK)SRRKScholar Rock Holding Corp

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Scholar Rock Holding Corp is currently not a strong buy due to its low RSI of 19.16, indicating oversold conditions, and a significant recent price decline of 9.87% over the last five days. However, the FDA approval of ISEMBYLD for SMA treatment presents a potential growth opportunity, supported by analyst price targets suggesting a 39% to 47% upside from the current price of $42.19. The main risk is the ongoing negative net income trend, with losses reported at -$109.9 million in Q2 2026.

4 analysts cover SRRK: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.